Kidney Neoplasms Clinical Trial
Official title:
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
NCT number | NCT01413607 |
Other study ID # | Dalhousieurosrs-2011 |
Secondary ID | |
Status | Terminated |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | September 2011 |
Verified date | July 2021 |
Source | Nova Scotia Health Authority |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to assess whether using a different type of suture (barbed sutures) during partial nephrectomy results in fewer postoperative complications than with traditional sutures (non-barbed). The most common complications are urine leakage and bleeding. The investigators believe the barbed suture is less technically difficult to use and will allow the surgeon to better repair the hole left in the kidney after the tumor is removed.
Status | Terminated |
Enrollment | 65 |
Est. completion date | |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - any person who is being treated for kidney cancer with partial nephrectomy. Exclusion Criteria: - those from whom we cannot obtain adequate informed consent. - those that are converted from partial to radical nephrectomy intraoperatively. |
Country | Name | City | State |
---|---|---|---|
Canada | CDHA QEII site | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Ricardo Rendon |
Canada,
Becker F, Siemer S, Kamradt J, Zwergel U, Stöckle M. Important aspects of organ-preserving surgery for renal tumors: indications, new standards, and oncological outcomes. Dtsch Arztebl Int. 2009 Feb;106(8):117-22. doi: 10.3238/arztebl.2009.0117. Epub 2009 Feb 20. Review. — View Citation
Becker F, Van Poppel H, Hakenberg OW, Stief C, Gill I, Guazzoni G, Montorsi F, Russo P, Stöckle M. Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol. 2009 Oct;56(4):625-34. doi: 10.1016/j.eururo.2009.07.016. Epub 2009 Jul 28. Review. — View Citation
El-Ghazaly, T.H. and Rendon, R.A. 2011. Perioperative outcomes of laparoscopic partial nephrectomy using self-retaining sutures (SRS) and early clamp removal versus conventional kidney and collecting system repair. Canadian Urological Association Journal 5(3 suppl 1) s3-s114 sub-article 66
Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, Kattan MW, Novick AC. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007 Jul;178(1):41-6. Epub 2007 May 11. — View Citation
Nguyen MM, Gill IS. Halving ischemia time during laparoscopic partial nephrectomy. J Urol. 2008 Feb;179(2):627-32; discussion 632. Epub 2007 Dec 21. — View Citation
Turna B, Frota R, Kamoi K, Lin YC, Aron M, Desai MM, Kaouk JH, Gill IS. Risk factor analysis of postoperative complications in laparoscopic partial nephrectomy. J Urol. 2008 Apr;179(4):1289-94; discussion 1294-5. doi: 10.1016/j.juro.2007.11.070. Epub 2008 Mar 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative bleeding | Patients will be considered positive for bleeding if they have any of gross hematuria, need for transfusion in the postoperative period not believed to be from intraoperative bleeding or need for angioembolization. | Data will be collected up to 12 weeks following the procedure | |
Primary | Urinary leakage | Urinary leakage is defined as any leakage requiring instrumentation (stent insertion, retrograde pyelogram or percutaneous drainage) or prolonged stay of drain due to high output (>4 days). | Data will be collected up to 12 weeks following the procedure | |
Secondary | Warm or cold ischemia time. | Warm is ischemia time is the time that the kidney is without blood perfusion while at body temperature. Cold ischemia time is the time the kidney is without blood perfusion while being cooled below body temperature. | Intraoperative | |
Secondary | Total operative time | Intraoperative | ||
Secondary | Length of hospital stay measured in days | Postoperative. Average stay following partial nephrectomy is 3 days | ||
Secondary | Estimated blood loss during the procedure | Intraoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00226980 -
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 |